China Medical University Hospital (CMUH) in Taiwan has achieved three HIMSS Digital Maturity Model validations, becoming the country’s first hospital to reach Stage 7 of the Infrastructure Adoption Model (INFRAM) and Stage 6 of the Adoption Model for Analytics Maturity (AMAM). It was also revalidated at Stage 7 for the Electronic Medical Record Adoption Model (EMRAM). Among its innovative technologies, CMUH’s Intelligent Anti-Microbial System (i.A.M.S), an AI platform that predicts and monitors infectious sepsis and recommends drug dosages, has reportedly helped reduce the mortality rate from sepsis by 7.1% within three months of its implementation.
China Medical University Hospital Achieves Major Digital Maturity Milestones
China Medical University Hospital (CMUH) in Taichung, Taiwan, recently reached significant benchmarks in three HIMSS Digital Maturity Models: Stage 7 for the Infrastructure Adoption Model (INFRAM), revalidation of Stage 7 for the Electronic Medical Record Adoption Model (EMRAM), and Stage 6 for the Adoption Model for Analytics Maturity (AMAM).
The INFRAM measures an organization’s maturity in infrastructure and technology capabilities, while the EMRAM gauges clinical outcomes, patient engagement, and clinician use of EMR technology. The AMAM assesses an organization’s analytics capabilities.
As the first hospital in Taiwan to achieve Stage 7 INFRAM, CMUH reached this milestone in just four months after reaching Stage 6. It attributes this to its infrastructure strategy, inspired by the Chinese Zodiac.
CMUH became Taiwan’s first hospital to reach Stage 6 AMAM by demonstrating mature analytics applications. This included analyzing medication expenses, which resulted in annual cost savings of approximately NT$ 200 million ($6.2 million). CMUH also introduced the ARDiTeX visualization panel in the Respiratory ICU, which helped reduce the 28-day mortality rate among patients with Acute Respiratory Distress Syndrome.
CMUH also underwent significant changes in its EMR system to satisfy Stage 7 EMRAM requirements, including the implementation of the Electronic Medication Administration Record, and establishing interoperability with Taiwan’s National Health Insurance Med-cloud database. Furthermore, HIMSS recognized CMUH’s Intelligent Anti-Microbial System (i.A.M.S.), an AI platform that cut the mortality rate due to sepsis by 7.1% in just three months after its implementation in June 2021.
Currently, CMUH has developed 16 AI-driven services and 50 dashboards on the Microsoft Power Business Intelligence platform, implemented broadly across clinical and operational areas.
Other Taiwanese healthcare providers validated for EMRAM include Changhua Christian Hospital and Kaohsiung Medical University Chung-Ho Memorial Hospital. CMUH’s AMAM and INFRAM validations follow Samsung Medical Center, the first healthcare provider in Asia-Pacific to achieve Stage 6 AMAM and Stage 7 INFRAM.
CMUH officials announced their digital transformation was inspired by international standards and models. They expressed their smart healthcare vision is centered on refining clinical processes and elevating care quality through data analytics and AI. This involves using advanced AI to deliver precise, efficient, and reliable medical solutions like i.A.M.S, with a strong commitment to enhancing patient care and quality of life.